Vaxart, Inc. - Common Stock revenue breakdown overview

Vaxart, Inc. - Common Stock revenue for the last year amounted to 28.70 M USD, the most of which — 28.70 M USD — came from its highest performing source at the moment, Oral Recombinant Protein Vaccines, the year earlier bringing 7.38 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Vaxart, Inc. - Common Stock 28.70 M USD, and the year before that — 7.38 M USD.